A phase I, single-institution open-label, dose-escalation trial with an expansion cohort evaluating the safety and tolerability of AZD6244 and IMC-A12 in subjects with advanced solid malignancies.
S. R. Ahmed
No relevant relationships to disclose
D. Cosgrove
No relevant relationships to disclose
D. Ball
No relevant relationships to disclose
R. C. Donehower
No relevant relationships to disclose
B. Nelkin
No relevant relationships to disclose
E. Petito
No relevant relationships to disclose
M. Downs
No relevant relationships to disclose
H. X. Chen
No relevant relationships to disclose
A. Doyle
No relevant relationships to disclose
A. Scardina
No relevant relationships to disclose
M. A. Carducci
No relevant relationships to disclose
N. S. Azad
No relevant relationships to disclose